Podcasts about Rett

I den grad pressen er opptatt av juss, er det stort sett straffesakene. Det er jo ikke så rart, pressen er jo her for Folk Flest, og også vi er er mest opptatt av krim. Men hvordan tenker journalistene som skriver eller podder om straffesaker om de ulike kryssende hensynene som gjør seg gjeldende ved dekning av slike saker? Mellom tragedie og underholdning, ytringsfrihet og personvern, vesentlige og uvesentlige opplysninger - og den tidvis uhellige symbiosen mellom de redaktørstyrte og sosiale medier? Anine spør, den erfarne og tenksomme krimjournalisten Øystein Milli, som deler Anines mål om å forklare kronglete juss på forståelige måter, svarer. Takk&lov! Hosted on Acast. See acast.com/privacy for more information.

Nytt medlem i redaksjonen, vanskelighetene og gledene med blindsmaking. Og kort om morgenurin.

Please visit answersincme.com/UMW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Neul, MD, PhD. n this activity, an expert in pediatrics and neurology discusses the latest data for treatment of Rett syndrome. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for investigational neuroactive pharmacologic therapies in the treatment of RTT; and Translate the latest data into treatment considerations for approved and emerging therapies in RTT.

On this week's episode, Graig Suvannavejh, Eric Schmidt, Paul Matteis and Financial Times' Oliver Barnes kicked off with the biotech market, with the XBI in positive territory and 12 biotech IPOs completed so far this year. They expected the IPO window to remain open for high-quality private companies. The group also overviewed recent financings, including SonoThera's $125 million Series B, City Therapeutics' $100 million Series B, Ethyreal's $101 million Series A, and Summit's decision to cancel a $500 million secondary offering. In data news, the co-hosts covered Tango's combination data with Revolution Medicines' RAS inhibitor. They also discussed Incyte's acquisition of Vega Therapeutics as a pipeline-building move ahead of Jakafi's 2028 patent expiration and J&J's acquisition of Firefly, with the RAS inhibitor space expected to remain hot. The group also discussed GSK's acquisition of Nuvalent -- its largest deal to date -- for two late-stage lung cancer assets. Oliver added perspective on biotech deal leaks, following the Incyte/Vega deal and GSK/Nuvalent deals this week. In partnership updates, Novartis expanded its molecular glue work with Orionis, Lilly licensed an Alzheimer's candidate from AlzeCure, and Corvus supported China partner Angel Pharmaceuticals. The episode concluded with the latest in rare disease and gene therapy, covering Novartis' FSHD program, FDA flexibility, Rett syndrome programs, and Sensorion's exit from hearing loss development. *This episode aired on June 12, 2026. 

Det er straks avspark for fotball-VM, og vi kan endelig ta fri fra jus noen uker. Eller? Også i fotball er det kronglete lover og regler med rom for skjønn - som offside og hands. Og jammen er det en verden rundt fotballen også, som fotballen må forholde seg til. Om VM nå er i Qatar eller USA. En verden av både politikk og jus. Hvordan vedtas og håndheves fotballens regler? Og hva er forholdet mellom dem og reglene i verden rundt - når idrettsutøvere utestenges for doping eller hormonnivåer, eller bøtelegges for å si noe politisk korrekt eller ukorrekt på banen? Er idretten unntatt fra menneskerettigheter som privatliv, rettferdig rettergang og ytringsfrihet? Anine spør, hennes tidligere kollega, nå juridisk direktør i Datatilsynet - og vedvarende fotballhistorisk og -juridisk leksikon svarer. Takk&lov! Hosted on Acast. See acast.com/privacy for more information.

In the fourth episode of this series, Dr. Stacey Clardy discusses care team essentials and working within multidisciplinary teams.  Show transcript:  Dr. Stacey Clardy: This is the Neurology Minute. I'm Stacey Clardy from the Salt Lake City VA and the University of Utah. This is our 4th episode in our four-part series on Rett syndrome. Today we're going to discuss care team essentials and working within multidisciplinary teams. Rett syndrome requires coordinated, ongoing, multidisciplinary care across the lifespan. So core team members will often include neurology, genetics, developmental pediatrics, gastroenterology, pulmonology, cardiology, orthopedics, and a range of rehabilitation specialists. Speech language pathology especially plays a central role, particularly through augmentive and alternative communication strategies, given the characteristic profound expressive language limitations in Rett syndrome. Care coordination obviously is essential, and neurologists will usually serve as the central point of integration, helping families navigate the complexities of care systems internationally and anticipating who might need to be brought in at certain times, given evolving needs. And caregiver input is especially critical in Rett syndrome patients because the patients have limited verbal communication. So it's these caregivers who are going to be able to provide key insights into daily neurologic status, behavior, and subtle clinical changes that clinicians may well not be able to detect in periodic short office visits. Another essential component is transition planning, right?  As Rett syndrome patients age, structured transition from pediatric to adult care systems is necessary, essential to maintain continuity and avoid fragmentation. And as in any rare disease, many families find that participation in specialty clinics, and registries, and clinical trials, when available, can provide access to evolving therapies and contribute to ongoing advances in the field. That's it for our Rett syndrome series. Be sure to listen to the three prior Neurology Minute episodes on Rett syndrome for a full overview. I'm Stacey Clardy for the Minute. 

In this Guest Interview, John and Chris welcome Rett Larson, a world renowned volleyball strength and conditioning coach. Rett has gold medals in the 2016 Olympics and 2015 World Cup amongst many other accolades. His 'No Zombies' approach and innovative warmups have taken social media by storm in the S&C field. In this episode, the guys discuss cultural differences in sports training, and practical tips for making warm-ups engaging and effective across various sports.**John, Chris and many of the show's guests are NOT licensed healthcare providers & make NO claims to be. The information provided in this show is not intended to be medical advice & should not be misconstrued as such. You assume all risk & liability by implementing any of the information shared on this show. You should ALWAYS seek the opinions of a qualified healthcare provider in your state/country before using any of the information provided in this show*Chapters00:00 Introduction to the Starting Block Podcast01:15 Meet Rhett Larson: A Journey in Strength Conditioning04:43 Cultural Insights from Coaching Abroad09:35 The Demand for American Coaches in Global Sports12:44 Learning from Different Training Philosophies19:58 No Zombies: A New Approach to Warmups28:24 Thermogenic Warm-Ups and Injury Prevention30:43 Cultural Adaptations in Coaching33:57 Innovative Training Techniques36:12 Creative Drills for Engagement48:49 Fun and Functional Training Methods

I dagens sending snakker Helena Edlund med opinionsleder og medieprofil Mojdeh Zandieh om Iran, Trumps handlinger og hvordan Vesten har sviktet det iranske folket – igjen. Også noen advarselsord om media og uhellige allianser – kan det som skjedde i Iran i 1979 ha en vestlig ekvivalent i våre land..?Hver morgen kl. 09.00 har Document en sending for deg. Mandag til onsdag sender vi «Rett på sak» med Espen Teigen. Et direkte og uredd nyhetsprogram for deg som er lei av NRK.Torsdag og fredag sender vi radiosendinger.

In the third episode of this series, Dr. Stacey Clardy discusses treatment options and ongoing management. Show transcript:  Dr. Stacey Clardy: This is The Neurology Minute. I'm Stacey Clardy from the Salt Lake City VA at the University of Utah. This is the third episode today in our four-part series on Rett syndrome, and we're going to talk about treatment options and ongoing management. There is still no curative therapy for Rett syndrome and management remains largely supportive and multidisciplinary. But there is now an FDA-approved treatment, trofinetide, for adults and children two years of age and older with Rett syndrome. Trofinetide is a synthetic analog of glypromate. It's thought to modulate neuroinflammation and synaptic function, right? Because Rett syndrome involves difficulty with synaptic function. Clinical trials demonstrated improvements in some of the core Rett symptoms, but of course, as always, treatment decisions are going to require an individualized discussion, particularly given some common adverse effects such as diarrhea and vomiting. Beyond disease-specific therapy, management remains symptom driven. Given that epilepsy is common and may be refractory, careful EEG correlations are often necessary. Of course, the breathing abnormalities like hyperventilation and apnea are fairly characteristic and can fluctuate over time so need to be monitored, and gastrointestinal dysfunction, nutritional challenges, other sleep disturbances, and scoliosis require ongoing monitoring and intervention when relevant. Rehabilitation therapies, physical, occupational, and speech, are foundational throughout life. A key principle here is anticipatory management, right? Many of the complications, like cardiac conduction abnormalities and bone health issues, can be identified early and addressed early with better outcomes when Rett syndrome patients have coordinated care. That's it for today. Be sure to listen to the other Neurology Minute episodes in this series on Rett syndrome, and check back for our next and final episode, where we will cover care team essentials and multidisciplinary management. I'm Stacey Clardy for the minute. 

Rett før fotball-VM sparkes i gang, løfter vi på dynene til de største idrettspampene. For der – bak glansbildet – skjuler det seg maktspill, skitne penger, kriminalitet og stormaktspolitikk. Møt sportssjournalist Andreas Selliaas i samtale med VG-journalist Henning Olsen. I sin nye bok, Det farlige spillet, tar sportsjournalisten Andreas Selliaas oss med til idrettens skyggesider, der autoritære regimer bruker idretten som politisk verktøy, mens maktpersoner bruker den til egen personlig vinning.Samtalen fant sted på Litteraturhuset Fredrikstad 4. mai 2026. Hosted on Acast. See acast.com/privacy for more information.

Discover the Rett syndrome clinical breakthroughs of 2025 and beyond. Credit available for this activity expires: 5/28/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/rett-syndrome-year-review-what-we-learned-and-beyond-2026a1000gtx?ecd=bdc_podcast_libsyn_mscpedu

In the second episode of a four-part series on Rett syndrome, Dr. Stacey Clardy discusses the importance of early referrals, particularly during the regression phase.  Show transcript:  Dr. Stacey Clardy:  This is the Neurology Minute. I'm Stacey Clardy from the Salt Lake City VA and the University of Utah. This is the second episode in a four-part series on Rett syndrome. Today, let's discuss when to refer and specifically early referral is absolutely critical in Rett syndrome, particularly during the regression phase. Any child, most often a girl with previously acquired developmental milestones who begins to lose language or lose purposeful hand use or develops stereotyped hand movements should prompt urgent neurologic evaluation. This would be referral to pediatric neurology, of course, and this should not wait for genetic confirmation. Early involvement of pediatric neurology allows for diagnostic clarification, anticipatory guidance, and coordination of care across systems. The genetic testing, typically with MECP2 sequencing and deletion or duplication analysis, this should be pursued early and if initial testing is negative but suspicion remains high, expanding that genetic evaluation is warranted. And beyond neurology, early engagement with developmental services, speech, occupational, and physical therapy should start before even a definitive diagnosis is necessarily established. Rett syndrome is a multi-system disorder. So a care team is going to monitor for common comorbidities. This is not just epilepsy, but also gastrointestinal dysfunction, breathing abnormalities, and orthopedic complications. When delayed referrals occur, it's often due to attribution of regression to more common developmental conditions. Be sure to listen to the other Neurology Minute episodes in this series. We'll be back next time for our third episode, and we'll cover treatment options and ongoing management.

Rett på DVD i dagens Nostalgi: Oppfølgeren til En Langbeint Film fra 1995. Max skal på Collage, men det skal også Langbein?!Er du glad i Harry Potter, gaming eller anime?Join Discord serveren vår!https://discord.gg/4J5hG8RStøtt oss gjerne på patreon: https://www.patreon.com/spillkveldSosiale medier:https://www.instagram.com/nordremedia/https://www.facebook.com/filmkamerateneyoutube/https://twitter.com/NordreMedia

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

Brain aging and disease research can gain new insights from space. Aline M.A. Martins, Ph.D., UC San Diego, explains how neuroscience studies in space use brain organoids, proteomics, and single-cell analysis to understand cognition decline, space-induced neurosenescence, and disease-related changes. Martins examines molecular markers of senescence, mitochondrial impairment, and neuroinflammation in organoid models, including Rett syndrome, while also comparing how space affects organoids of different ages. She shows that space can accelerate aging-related changes and affect cell types differently, helping clarify how space biology may speed drug discovery and reveal biomarkers for disease. This work helps explain how space research can inform treatments on Earth and points toward faster preclinical testing and broader understanding of brain disease. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41478]

In the first episode of a four-part series, Dr. Stacey Clardy discusses the diagnosis and clinical presentation of Rett syndrome.   

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically rich conversation on leadership, commercialization, and the future of neuropsychiatry. From starting as a pharmacist in the UK to pivoting from R&D into commercial leadership at Johnson & Johnson, rising through Bristol Myers Squibb, and ultimately stepping into her first biotech CEO role at Acadia, Catherine shares how storytelling became the throughline of her career—transforming science into physician trust, investor conviction, and enterprise vision. In this episode, Catherine opens up about the personal family experiences with neurodegenerative disease that made Acadia's focus on CNS and rare disease feel like her “Goldilocks opportunity.” She offers a candid look at the realities of being a first-time CEO, managing investor ecosystems, building the right C-suite, balancing billion-dollar commercial execution with high-risk R&D, and navigating the emotional stakes of developing therapies for Parkinson's disease psychosis, Alzheimer's disease psychosis, Rett syndrome, and beyond. Rahul and Catherine also explore the seismic shifts reshaping biotech—from AI-powered commercialization and patient services to policy advocacy through BIO, FDA modernization, and the strategic pressures facing CNS innovation. This episode is both a masterclass in biotech leadership and a powerful reminder that the best CEOs don't just run companies—they tell stories that move science, markets, and patients forward. Biography: Ms. Owen Adams joined Acadia as Chief Executive Officer and as a member of our Board of Directors in September 2024. Ms. Owen Adams has over 25 years of executive level experience in the pharmaceutical industry. Prior to joining Acadia, Ms. Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (BMS), where she led a $20 billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology. Previously, Ms. Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS, where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS's merger with Celgene. Prior to her tenure at BMS, Ms. Owen Adams spent 25 years at Johnson & Johnson (J&J), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Ms. Owen Adams began her career in R&D and manufacturing at AstraZeneca. Ms. Owen Adams currently serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms. Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a non-profit organization. Ms. Owen Adams earned a BSc. in Pharmacy from the University of Manchester, becoming a qualified pharmacist and member of the Royal Pharmaceutical Society (MRPhS).

Rett nedenfor velstående Holmenkollen i Oslo ligger Hovseter. For første gang er vestkantstedet med på politiets oversikt over steder med ekstra utfordringer. Vi oppsummerer nyhetene for deg, i dag også om Mímir Kristjánssons nye bibelbok.

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

Dette er en episode i HELP-podkasten «Rett skal være rett for alle» om gjensidige testamenter for samboere. Vi forklarer hva testament er, forskjellen mellom samboere og ektefeller, formelle krav til testament, betydningen av samboeravtale og praktiske råd om bolig, arv og oppbevaring av testamentet. Episoden er ved arverettsadvokat Tina Berg og kommunikasjonsdirektør Dag Are Børresen. Lyd: Francesco Hygen Puddu. 

I denne episoden av "Rett skal være rett. For alle" fra advokatene i HELP går vi gjennom fordeler og ulemper ved å gi gaver i levende live kontra å skrive testament, hvordan uskifte og livs- og dødsdisposisjoner kan påvirke muligheten til å gi gaver, og hvorfor store gaver i form av fast eiendom krever realitet for å unngå risiko for omstøtelse. Vi forklarer også forskudd på arv, gavebrev, dokumentavgift ved overføring av fast eiendom og mulige skattemessige konsekvenser for mottaker. Råd: få skriftlig dokumentasjon og rådfør deg med advokat. Episoden er ved HELPs advokater Mona Danielsen og Dag Are Børresen. Lyd: Francesco Hygen Puddu.

"Rett skal være rett. For alle" er en podkast fra advokatene i HELP. I denne episoden snakker vi om arveregler, testament og hvorfor formuesordninger som felleseie og særeie er viktige å kjenne til før du skriver testament. Vi forklarer forskjellen mellom felleseie og særeie, hvordan ektepakten fungerer, hvordan testament og særeie kan sikre at viktige eiendeler som hytta går dit du ønsker, og hvilke begrensninger arveloven setter for testamentsfriheten. Praktiske råd: Snakk med ektefelle og arvinger, dokumenter eventuelle forskudd på arv, og kontakt advokat for å få laget testament og eventuelt ektepakt som fungerer i din situasjon. Episoden er ved HELPs advokater Mona Danielsen og Dag Are Børresen. Lyd: Francesco Hygen Puddu. 

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

I dagens sending snakker Hans Rustad og Helena Edlund om aktuelle saker.Hver morgen kl. 09.00 har Document en sending for deg. Mandag til onsdag sender vi «Rett på sak» med Espen Teigen. Et direkte og uredd nyhetsprogram for deg som er lei av NRK.Torsdag og fredag sender vi radiosendinger.

Rett på sak er direkte tydelige meninger og usensurerte nyheter kl. 09.00.Som alltid får du de usensurerte nyhetene og ærlige perspektivene du ikke finner hos NRK.Kom gjerne med forslag til saker ved å sende oss en e-post eller skrive i kommentarfeltet.

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

Brain aging and neurological disease are hard to study because living human brain tissue is difficult to access. Alysson Muotri, Ph.D., UC San Diego, explains how brain organoids sent to space can model accelerated aging, reveal changes in neural networks, and help test potential treatments for brain disorders. Muotri examines space-induced senescence, fragmented network activity linked to dementia and Alzheimer's patterns, and Rett syndrome findings showing inflammation tied to endogenous retroviruses and response to antiretroviral drugs in preclinical models. He also explores using brain organoids in space to screen neuroprotective compounds, including candidates identified from Amazon plants. This work helps explain how space biology can speed research on autism, Rett syndrome, Alzheimer's disease, and other neurological conditions, and points toward new ways to test therapies on Earth. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 41475]

This week Rett gets infected with space madness as we look back at 2009's sci fi horror film Pandorum. Rett considers this film a hidden gem akin to Dark City or Event Horizon - unappreciated at release but an interesting film with several shocking twists and turns. https://www.spreaker.com/episode/pandorum--71635500

Rett is a physical preparation coach with an extensive and diverse background. He has worked internationally with the national volleyball teams of Germany, Netherlands and China. Rett has also worked with professionals, down to athletes of all ages, having prior experience as Velocity Sports Performance's director of coaching in California. Rett is a student of movement, having studied not only the top minds in sports performance, but also in general movement training such as taught by Ido Portal and in the scope of physical education. 02:40 - The fun of working some beach pros, along with a slew of other athletes, helping players hone their skill that fits the situation 09:29 - "No Zombies" in practice explained, warmups that galvanize practice, practice plans that are appropriate for the game preparation and post performances 20:20 - Moves that you think athletes NEVER practiced, but they do, using examples in MMA and beach volleyball, the advantages indoor players have cross training on the beach 29:13 - Understanding why "No Zombies" is sustainable, and on the opposite end why "going through the motions" is not always a bad thing, why guys like him doing his job helps guys like me do our job 42:20 - What does skills over drills really mean? Where "taking care of your side of the net" applies, the players who understand coaching is a different occ 57:21 - Where being physically ready improves the mental, playing your percentages, the real scientists? Are us. 1:07:00 - "Don't try this at home," or should we? Plus, consequence drills: What if she can't go (mentally)? 1:25:03 - Conventional warmups, non-conventional warmups and the adjustments, the vast library, the fun in competitive, interesting inspiring reads

Last year, Wes showed El Mariachi to Rett. This week Rett is firing back at Wes' Robert Rodriguez pick and raising him Spy Kids, a quintessential movie for any self respecting millennial! From day dreaming about the rehydrator to uncovering trivia about the nightmarish Thumb Thumbs, we had a great time experiencing and reliving this 2000's classic.https://www.spreaker.com/episode/spy-kids--70881781#robertrodriguez #spykids #millenial

Freiburg og Mainz med rekordsuksess i Europa! Köln-trener Kwasniok erklærer at han er rett mann for rett lag til rett tid. Dagen etter får han sparken. Asbjørn mimrer om et historisk mål som er nesten like gammelt som ham selv. Vi anbefaler film for landslagspausen. Applaus for Jonas Therkelsen, tenk at en nordmann skulle avgjøre MOT Bochum!See omnystudio.com/listener for privacy information.

Hva er det som skjer i den nye Grandiosareklamen?! Og hvorfor henger ikke hjemløse og lutfattige på IKEA? Irriterer meg også over Joe Rogan sin gigantiske inkompetanse og gikk dypt nedi et kaninhull med katter i fallskjerm og andre dyr. Mye gøy og mye fjas. Rett og slett en herlig episode.Og kom dere på show denne uken folkens! Onsdag og torsdag! https://www.ticketmaster.no/artist/christoffer-schjelderup-billetter/983426 Hosted on Acast. See acast.com/privacy for more information.

Interview with Dr. Mark Williams, President & CSO, and  J. Roderick Matheson, Director & CEO of Marvel Bioscience Corp.Recording date: 16th March 2026Marvel Biosciences is advancing MB-204, a first-in-class treatment for social withdrawal conditions across autism spectrum disorder, depression, and Alzheimer's disease. The clinical-stage biotechnology company targets an underserved therapeutic area affecting millions globally, with autism prevalence reaching one in 36 children in the United States and depression impacting one in eight adults currently on antidepressants. The addressable market spans hundreds of billions of dollars in healthcare costs and lost productivity.The compound is based on a modified version of an approved Parkinson's medication, providing an established safety foundation for clinical development. Preclinical data demonstrates rapid symptom reversal within one hour of oral dosing in animal models. In head-to-head comparisons, MB-204 outperformed trofinetide, the only FDA-approved Rett syndrome treatment, across all measured behavioral endpoints. Critically, animals treated with MB-204 maintained improvements for two to three weeks after treatment cessation, suggesting semi-permanent neurological changes, while trofinetide benefits disappeared immediately upon stopping.Marvel's clinical strategy prioritizes orphan disease indications, specifically Rett syndrome and Fragile X syndrome, where Phase 3 success rates exceed 50% due to genetically homogeneous patient populations and validated regulatory pathways. The company has completed manufacturing of clinical-grade material and toxicology studies, positioning MB-204 for immediate Phase 1 entry in Australia within six to twelve months. The Australian regulatory environment offers efficient processes and a 43% research tax credit that significantly reduces development costs.Marvel holds composition of matter patents in China and Japan, with additional jurisdictions pending. The company has engaged in preliminary partnership discussions, aligning with neuroscience sector dynamics where approximately 70% of companies complete licensing or acquisition deals before Phase 2. Historical precedents show neuroscience acquisitions typically occur at valuations exceeding $80 million at this stage. Trading at $9 million CAD market capitalization, Marvel represents a significant discount to comparable Phase 1 neuroscience firms, with several peers valued between $100-400 million.Sign up for Crux Investor: https://cruxinvestor.com

Rett syndrome is a rare neurodevelopmental disorder that disrupts a child's ability to purposely use their hands, communicate, and move around. It creates a lifelong caregiving burden for families, and there are still no treatments that truly change the course of the disease. Neurogene is developing a one-time gene therapy that has shown promising early results, with children gaining new skills and continuing to make developmental progress over time. We spoke with Rachel McMinn, CEO of Neurogene, about Rett syndrome, the company's technology for controlling gene expression, and the encouraging data they've seen so far.

Tuesday, February 17, 2026 - Week 8   We are flat out, thank you to the team who work full-time on SYNGAP1: VM KAH LP PP & KF.   CLINICAL TRIAL DESIGN We are Angelman-like. (Rett also) https://aesnet.org/abstractslisting/differentiating-key-symptoms-of-angelman-syndrome-as-and-syngap1-via-caregiver-reported-and-us-claims-data-to-understand-differences-between-how-providers-and-caregivers-view-impacts-on-patient-care Dravet or Angelman?  Phase 1/2 is when we try it all.  EEGs and NHS help with this effort.   BIOSAMPLES & EEGs! Biorepository needs more samples.  Check out the list and map here https://combinedbrain.org/roadshow/ and contribute both blood & EEGs.  The data and research we do with these samples is invaluable.  Let us know if you are going, email our CSO@curesyngap1.org.   (Stay tuned for another exciting device study…)   NATURAL HISTORY STUDY Sign up for Citizen Health cureSYNGAP1.org/Citizen and ProMMiS cureSYNGAP1.org/ProMMiS NHS Survey in English: https://curesyngap1.org/SurveyProMMiS & Spanish: https://curesyngap1.org/encuestaProMMiS Latest Pod on NHS: https://youtu.be/7W38uWKBIAw?si=lCrffwMXidmYWz7t   FUNDRAISING - SPRINT4SYNGAP Sprint is April 25 - our calendar page - cureSYNGAP1.org/Sprint - has all the information in the following links: set up your team - cureSYNGAP1.org/Sprint26 resource guide for your event - cureSYNGAP1.org/S4SGuide webinar #99 to help get you started - cureSYNGAP1.org/S4S25   Also, May 28, San Francisco, CA: cureSYNGAP1.org/SF26 Scramble for Syngap - 5th annual on October 3 in S. Carolina cureSYNGAP1.org/Scramble26   PUBMED Pubmed 2026 is at 9! https://pubmed.ncbi.nlm.nih.gov/?term=syngap1&filter=years.2026-2026&sort=date (Remember we had 18 in all of ‘18) Cool connection to #PraderWilli Syndrome. https://www.linkedin.com/posts/graglia_syngap1-praderwilli-autism-share-7429579885985296385-zuIH   ETC - More warriors cureSYNGAP1.org/Warrior - Dr. Donlin-Asp Press Release cureSYNGAP1.org/PR42 see talk here https://www.youtube.com/watch?v=lR8qcZK-9ro - Bravo Sara Driscol and GeneDx https://www.linkedin.com/posts/genedx_beyondawareforrare-ugcPost-7427763511235248129-QPPL?utm_source=share&utm_medium=member_desktop&rcm=ACoAAAAD8f4B7JC4TMss45Q8hrsq5kiceI0Z8HE   SOCIAL MATTERS 4,686 LinkedIn.  https://www.linkedin.com/company/curesyngap1 1,520 YouTube.  https://www.youtube.com/@CureSYNGAP1 11.2k Twitter https://twitter.com/cureSYNGAP1 45k Insta https://www.instagram.com/curesyngap1   $CAMP stock is at $3.85 on 17 Feb. ‘26 https://www.google.com/finance/beta/quote/CAMP:NASDAQ   Like and subscribe to this podcast wherever you listen.  https://curesyngap1.org/podcasts/syngap10/ Episode 199 of #Syngap10 #CureSYNGAP1 #Podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of insightful updates that highlight the dynamic and rapidly evolving nature of these sectors, driven by scientific advancements, regulatory shifts, and strategic industry maneuvers.Starting with Merck, which is strategically planning for a post-Keytruda era, projecting over $70 billion in annual opportunities over the next decade. With Keytruda's patent expiration looming in 2028, Merck is actively expanding its portfolio through acquisitions and partnerships, focusing on oncology and immunology. These areas have been significantly impacted by Keytruda's success, and Merck's proactive approach aims to sustain growth and innovation beyond its current flagship product. During their 2025 full-year earnings call, CEO Robert Davis emphasized their expansive pipeline, highlighting recent strategic deals as pivotal to Merck's robust pipeline—the broadest it has been in years—signaling long-term growth through diversified therapeutic areas and innovative drug candidates.The U.S. Food and Drug Administration (FDA) is making waves with its regulatory approach to CAR-T cell therapies for autoimmune diseases. This shift reflects an increasing recognition of the potential these therapies hold for transforming treatment paradigms for conditions like lupus and multiple sclerosis. By offering a more flexible regulatory framework, the FDA is encouraging innovation while maintaining a focus on patient safety.In other regulatory news, AstraZeneca faces a setback with the FDA's rejection of its subcutaneous version of Saphnelo for lupus. The decision underscores the challenges associated with developing more patient-friendly administration methods for biologics. However, AstraZeneca remains optimistic about achieving a quick turnaround in the approval process, which could enhance patient adherence by offering a self-administered alternative to intravenous infusions.Sanofi finds itself in the spotlight after CEO Paul Hudson was sanctioned by the UK's Prescription Medicines Code of Practice Authority for making overly ambitious claims about Pfizer's RSV vaccine. This incident illustrates the competitive nature of vaccine procurement and underscores the importance of accurate communication by pharmaceutical leaders.In Massachusetts, Thermo Fisher Scientific is reducing its workforce with the closure of its Franklin site, impacting around 200 employees. This move is part of broader strategic realignments within the industry aimed at optimizing operations and focusing resources on high-growth areas.Acadia Pharmaceuticals faces potential rejection by the European Union for its drug trofinetide intended for Rett syndrome. This highlights ongoing challenges in gaining approval for treatments targeting rare diseases, despite their significant unmet needs.Meanwhile, GSK plans to lay off up to 350 R&D workers across the U.S. and UK as part of efforts to streamline operations and focus on core therapeutic areas. Such layoffs reflect broader industry trends toward consolidation and efficiency amid rising R&D costs.On a more promising note, Pfizer's GLP-1 receptor agonist has demonstrated significant results in a Phase 2b trial for weight loss, validating their substantial investment in this area. The drug's potential to offer competitive weight loss results with monthly dosing positions it as a strong contender in the obesity treatment market. Additionally, Pfizer continues to accelerate its efforts in obesity treatment with promising mid-stage trial results for PF-3944, showing up to a 12.3% weight loss at 28 weeks. This suggests Pfizer is keen on expanding its presence in obesity management through strategic clinical development as competition within this therapeutic area intensifies.The U.S. Department of Health and HumanSupport the show

Deborah Ward | Point of View HR At Point of View HR Consulting, we help business leaders align their business goals with their Human Resources Operations. We offer a complimentary consultation to uncover the HR priorities and needs to develop a customized roadmap, addressing both strategic and operational objectives. A few areas of expertise include […]

Deborah Ward | Point of View HR At Point of View HR Consulting, we help business leaders align their business goals with their Human Resources Operations. We offer a complimentary consultation to uncover the HR priorities and needs to develop a customized roadmap, addressing both strategic and operational objectives. A few areas of expertise include […]

Jólin búin. Amorim búinn, Maresca búinn, löng drive, nærbuxur í sundi.